1. Home
  2. NXRT vs COLL Comparison

NXRT vs COLL Comparison

Compare NXRT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXRT
  • COLL
  • Stock Information
  • Founded
  • NXRT 2014
  • COLL 2002
  • Country
  • NXRT United States
  • COLL United States
  • Employees
  • NXRT N/A
  • COLL N/A
  • Industry
  • NXRT Real Estate Investment Trusts
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXRT Real Estate
  • COLL Health Care
  • Exchange
  • NXRT Nasdaq
  • COLL Nasdaq
  • Market Cap
  • NXRT 1.2B
  • COLL 1.1B
  • IPO Year
  • NXRT N/A
  • COLL 2015
  • Fundamental
  • Price
  • NXRT $37.35
  • COLL $32.91
  • Analyst Decision
  • NXRT Buy
  • COLL Strong Buy
  • Analyst Count
  • NXRT 5
  • COLL 5
  • Target Price
  • NXRT $49.00
  • COLL $43.80
  • AVG Volume (30 Days)
  • NXRT 139.3K
  • COLL 524.5K
  • Earning Date
  • NXRT 02-18-2025
  • COLL 02-20-2025
  • Dividend Yield
  • NXRT 5.46%
  • COLL N/A
  • EPS Growth
  • NXRT 54.64
  • COLL 757.11
  • EPS
  • NXRT 1.77
  • COLL 2.16
  • Revenue
  • NXRT $264,974,000.00
  • COLL $599,245,000.00
  • Revenue This Year
  • NXRT N/A
  • COLL $13.20
  • Revenue Next Year
  • NXRT $0.54
  • COLL $17.63
  • P/E Ratio
  • NXRT $21.12
  • COLL $15.22
  • Revenue Growth
  • NXRT N/A
  • COLL 9.62
  • 52 Week Low
  • NXRT $28.20
  • COLL $28.39
  • 52 Week High
  • NXRT $48.37
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • NXRT 22.77
  • COLL 63.29
  • Support Level
  • NXRT $40.77
  • COLL $28.53
  • Resistance Level
  • NXRT $42.14
  • COLL $29.58
  • Average True Range (ATR)
  • NXRT 1.07
  • COLL 1.26
  • MACD
  • NXRT -0.45
  • COLL 0.48
  • Stochastic Oscillator
  • NXRT 1.11
  • COLL 79.87

About NXRT NexPoint Residential Trust Inc.

NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: